-
Teva Offers Drugs Valued at $23 Billion to Opioid - Bloomberg
-
Teva Adderall Supply Continuing for 2-3 Months (1)
-
Teva Pharma's Short Sellers Double Down as Legal Woes On - Bloomberg
-
Teva says its generic shortage will last another 2 to months (NYSE:TEVA) | Seeking Alpha
-
Teva to lay off 25% workforce, suspends - BNN Bloomberg
-
Agrees to Settle Opioid Lawsuits as Much as $4.25 Billion - WSJ
-
Teva CEO Calls 'Trough' Consequence Patent Expirations - YouTube
-
Price-fixing lawsuit deals another blow to already fragile Teva, experts say | of Israel
-
of Cloning a CEO - Bloomberg
-
CEO to Netanyahu With Blunt on Need for Cuts Bloomberg
-
Teva Is Facing Adderall Supply Disruptions as Demand for Soars - Bloomberg
-
Teva Pharmaceutical to CEO Kare Schultz - WSJ
-
Teva Wins Challenge Over Key Novartis Drug Patents (1)
-
New jury drug firm Teva liable in opioid crisis
-
Tags search |
-
Teva Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
-
Buffett's Berkshire Takes Activision Blizzard Stake, Exits Teva - BNN
-
Teva's Budding Blockbuster Drugs Lend From Legal Concerns - Bloomberg
-
Illinois eligible portion of $4 billion Teva opioid settlement Crain's Chicago
-
Teva Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
-
makes $40B bid for Mylan
-
Activist Investor Jana Partners Takes Stake in Teva, Report Says Ctech
-
Teva's free drug opioid settlement be a great deal in the long run: analyst |
-
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, Says |
-
Future CEO Seeks to 'Formulate - YouTube
-
Pharma's Short Double Down as Legal Woes Drag On - BNN Bloomberg
-
Teva's Credit Rating Cut to by Fitch - Bloomberg
-
Teva flags supply constraints ADHD Adderall as demand (NYSE: TEVA) | Seeking Alpha
